Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAXUS stent
- Development stage
- Unknown
- Lead developer
- Boston Scientific
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Implant, Percutaneous
01
Overview
The TAXUS stent is a drug-eluting coronary stent system developed by Boston Scientific for the treatment of coronary artery disease. It consists of a metallic stent platform coated with a proprietary polymer, Translute, which facilitates the controlled, sustained release of the active pharmaceutical ingredient, paclitaxel. Paclitaxel is a small molecule that binds to tubulin and stabilizes microtubules, thereby inhibiting the migration and proliferation of vascular smooth muscle cells—a process known as neointimal hyperplasia that leads to restenosis. The TAXUS product line includes several generations: the TAXUS Express (stainless steel), TAXUS Liberté (thinner stainless steel struts), and TAXUS Element (platinum-chromium, also known as ION in the United States). It was one of the first drug-eluting stents to receive FDA approval (2003) and has been widely used in percutaneous coronary interventions.
- Brand names
- TAXUSTAXUS ExpressTAXUS LibertéTAXUS ElementION
- Other names
- TAXUS drug-eluting stentPaclitaxel-eluting stent
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TAXUS stent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAXUS stent.